The invention relates to buffer substances for the phase-appropriate treatment of wounds, said treatment comprising the suppression of fibrin formation and/or fibrin cross-linking. The invention further relates to a wound dressing product containing said buffer substances to suppress fibrin formation and/or fibrin cross-linking.
